CohBar (NASDAQ:CWBR) Issues Earnings Results, Misses Expectations By $0.01 EPS

CohBar (NASDAQ:CWBR – Get Rating) released its earnings results on Monday. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01), MarketWatch Earnings reports. During the same quarter in the previous year, the firm posted ($0.07) EPS.

Shares of CohBar stock opened at $0.20 on Wednesday. The stock has a market capitalization of $17.40 million, a P/E ratio of -0.95 and a beta of 2.49. CohBar has a 52-week low of $0.18 and a 52-week high of $2.27. The stock’s 50-day simple moving average is $0.27 and its 200 day simple moving average is $0.36.

Separately, Zacks Investment Research upgraded CohBar from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a research note on Friday, April 1st.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC bought a new stake in shares of CohBar in the third quarter valued at approximately $86,000. BlackRock Inc. grew its stake in CohBar by 11.5% in the 4th quarter. BlackRock Inc. now owns 390,364 shares of the company’s stock valued at $136,000 after buying an additional 40,298 shares in the last quarter. Millennium Management LLC raised its holdings in CohBar by 41.7% during the 3rd quarter. Millennium Management LLC now owns 203,040 shares of the company’s stock valued at $195,000 after acquiring an additional 59,732 shares during the period. Geode Capital Management LLC lifted its position in shares of CohBar by 32.5% during the third quarter. Geode Capital Management LLC now owns 475,936 shares of the company’s stock worth $456,000 after acquiring an additional 116,656 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of CohBar in the fourth quarter worth $657,000. Hedge funds and other institutional investors own 22.10% of the company’s stock.

CohBar Company Profile (Get Rating)

CohBar, Inc, a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease.

Recommended Stories